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After the COVID-19 outbreak, non-evidence based guidelines were published to advise
clinicians on the adjustment of oncological treatment during this pandemic. As immune
checkpoint inhibitors directly affect the immune system, concerns have arisen about the
safety of immunotherapy during this pandemic. However, data on the immune response in
oncology patients treated with immunotherapy are still lacking. Here, we present the
adaptive immune response in a SARS-CoV-2 infected patient who was treated with
immune checkpoint inhibitors for advanced renal cell cancer. To evaluate the immune
response in this patient, the number of T cells and their major subsets were measured
according to expression of markers for co-signalling, maturation, and chemotaxis at
baseline, during therapy, and during the SARS-CoV-2 infection. In addition, plasma
samples were analyzed for IgM and IgG antibodies and the ability of these antibodies to
neutralise SARS-CoV-2. Despite several risk factors for an impaired immune response to
SARS-CoV-2, both T- and B-cell responses were observed. Moreover, after treatment
with immune checkpoint inhibitors, a sufficient cellular and humoral immune response was
achieved in this SARS-CoV-2 infected patient. These findings warrant renewed discussion
on withholding of immune checkpoint inhibitors during an ongoing COVID-19 pandemic.
Keywords: immunotherapy, adaptive immunity, cellular, humoral, kidney neoplasms, cancerINTRODUCTION
The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), is having significant impact on oncological care. Besides capacity
issues, concerns have arisen about the safety of oncological treatment and an increased risk for a
more severe outcome of COVID-19 in patients with cancer (1–7). Patients with an (active)
malignancy may have an increased risk of severe COVID-19, and it is still not known whether
treatment with anti-cancer drugs—including immune checkpoint inhibitors (ICIs)—is safe during
this pandemic (1–5).org February 2021 | Volume 12 | Article 6271861
de Joode et al. Case Report: SARS-CoV-2 After Immune Checkpoint InhibitorsAfter the first COVID-19 outbreak, non-evidence based
guidelines were published to advise clinicians on the
adjustment of oncological treatment during this pandemic. As
ICIs directly affect the immune cells, and symptoms of COVID-
19 resemble adverse events of ICIs (8), these guidelines were
rather conservative regarding the use of ICIs during this
pandemic. However, data on the immune response in patients
infected with SARS-CoV-2 and treated with ICIs are still lacking
(9). Here, we present for the first time data of the T and B cell
responses in a SARS-CoV-2 infected patient who was treated
with nivolumab and ipilimumab for advanced renal cell
cancer (RCC).CASE DESCRIPTION
In 2019, a 62-year-old male, with diabetes mellitus type II and
hypertension, was diagnosed with primary metastatic RCC with
lung and bone metastases. The disease was complicated by
paraneoplastic pulmonary embolism for which therapeutic doses
of low molecular weight heparin were started. Based on an interval
of <1 year between diagnosis and systemic therapy, the patient had
an “intermediate risk” according to the International Metastatic
Renal Cell Carcinoma Database Consortium (IMDC) criteria.
Therefore, first-line treatment with 3-weekly ipilimumab (1 mg/
kg) plus nivolumab (3 mg/kg) was started while the primary tumor
was in situ (10). After four cycles of ipilimumab plus nivolumab, the
first response evaluation showed progressive disease according to
the Response Evaluation Criteria in Solid Tumours (RECIST) v1.1.
However, as the patient experienced clinical benefit and some target
lesions showed a reduction in tumor size with computed
tomography (CT), maintenance treatment with nivolumab was
started. After three cycles of 2-weekly maintenance treatment
with nivolumab, creatinine levels increased from 126 µmol/L (i.e.,
baseline prior to ICI) to 265 µmol/L (>2x ULN) and the estimated
glomerular filtration rate (eGFR) decreased from 53 ml/min (i.e.,
baseline prior to ICI) to 21 ml/min, which was accompanied by
erythrocyturia and proteinuria. After the exclusion of other possible
causes such as dehydration and contrast nephropathy, an immune
related nephritis was considered most likely, although a biopsy to
confirm this diagnosis could not be performed. According to the
Common Terminology Criteria for Adverse Events Version 5
(CTCAE v5), the patient experienced a treatment-related
nephritis grade 2 and treatment with steroids (prednisolone 1mg/
kg) was started, whereas maintenance treatment with nivolumab
was discontinued. In March 2020, the patient developed
symptomatic COVID-19 with coughing and dyspnoea, infection
with SARS-CoV-2 was confirmed by real-time polymerase chain
reaction (RT-PCR). At the time of hospital admission (2 days after
the onset of symptoms), the patient had been treated with
prednisolone (1mg/kg daily) for four weeks and the last dose of
nivolumab had been administered six weeks earlier. At that time,
the creatinine level was decreased to 163 µmol/L with an eGFR of 38
ml/min. To prevent a potentially severe course of COVID-19,
prednisolone was rapidly reduced to 60 mg daily within 3 days.
As this dose reduction of prednisolone was accompanied by a gradeFrontiers in Immunology | www.frontiersin.org 24 renal failure (creatinine level 500 µmol/L (>6.0 x ULN), eGFR 10
ml/min) according to CTCAE v5, high dose steroids (prednisolone
2 mg/kg daily, intravenously) was restarted. At hospital admission,
empiric antibiotic treatment with cefuroxime and azithromycin was
administered and minimal oxygen therapy was given for a few days.
After 12 days of admission, the patient could be discharged.
However, the patient was re-admitted within 7 days due to
clinical deterioration. CT and magnetic resonance imaging (MRI)
revealed extra- and intracranial progressive disease of RCC. MRI
showed a newly diagnosed brain metastasis with bleeding. The
patient experienced severe neurological deterioration and eventually
died within 1 month after the first hospital admission for COVID-
19. An autopsy was not performed.IMMUNE RESPONSE
To study the adaptive immune response in this patient,
peripheral blood samples were collected in the context of the
MULTOMAB study (Netherlands Trial Registry number
NL6828). In this observational study, blood samples are
prospectively collected from patients with cancer treated with
monoclonal antibodies. The MULTOMAB study has been
approved by the medical ethics committee at Erasmus Medical
Centre and the patient had signed informed consent. Blood
samples were collected at baseline (prior to the first
administration of ipilimumab plus nivolumab), 3 weeks after
the first administration of ipilimumab plus nivolumab (T1), and
during hospital admission for COVID-19 (23 weeks after the first
administration of ipilimumab plus nivolumab;T2).
After collection of these blood samples, peripheral blood
mononuclear cells (PBMCs) and plasma were isolated for
further analyses. Frequencies of T cells and their subsets prior
to and during treatment with ICIs were determined by multiplex
flow cytometry. The number of T cells and their major subsets
were measured according to the expression of markers for co-
signalling, maturation, and chemotaxis as previously described in
detail (11). In addition, plasma samples were analyzed for IgM
and total IgG antibodies directed against the receptor binding
domain (RBD) of SARS-CoV-2 using an ELISA (Wantai) (12),
and these antibodies were analyzed for their ability to neutralise
SARS-CoV-2 by a plaque reduction test (PRNT50) (13). Upon
diagnosis of COVID-19, the adaptive immune parameters
changed drastically. First, the counts of total leukocytes showed
a strong decrease from 6,9x103/µl at T1 to 3.9 x103/µl at T2,
which was predominantly caused by a decrease in lymphocyte
counts (Supplementary Table 1) (14, 15). Second, for both CD4
+ and CD8+ T cells the fractions of central (CD45RA-, CCR7+)
and effector (CD45RA-, CCR7-) memory T cells decreased,
whereas those of naïve T cells (CD45RA+, CCR7+) increased
when comparing T2 versus T1 and baseline (Figure 1). As the
total numbers of CD4+ and CD8+ T cells did not differ over
time, the observed increase in naïve T cells may have been the
result of apoptosis-mediated loss of more differentiated T cells.
Third, the fractions of CD4+ and CD8+ T cells expressing
multiple (≥2) types of co-inhibitory, co-stimulatory, and/orFebruary 2021 | Volume 12 | Article 627186
de Joode et al. Case Report: SARS-CoV-2 After Immune Checkpoint Inhibitorschemoattractant receptors increased when comparing T2 versus
T1 (Figures 2A–C). The last two observations indicate that
SARS-CoV-2 may have induced expression of multiple T cell
receptors, which is often considered a measure of T cell
differentiation. It is noteworthy that CD8+ T cells mainly
expressed co-inhibitory and co-stimulatory receptors, whereas
CD4+ T cells mainly expressed co-inhibitory receptors. In
particular, fractions of CD4+ T cells expressing both
programmed cell death protein 1 (PD-1) and B- and T-
lymphocyte attenuator (BTLA) were high during infection with
SARS-CoV-2 (Figure 2D). Fourth, the patient started to develop
SARS-CoV-2 specific IgM and IgG antibodies at 10 days post
onset of symptoms and neutralising antibodies were detectable at
15 days post onset of symptoms (Supplementary Table 2).
Altogether, the above-mentioned T and B cell responses in this
patient were assessed sufficient to clear the virus from the
respiratory tract, as demonstrated by a negative virus culture at
15 days post onset of symptoms. The prolonged shedding of viralFrontiers in Immunology | www.frontiersin.org 3RNA is a phenomenon which is often observed, but does not
necessarily indicate presence of infectious virus (16).DISCUSSION
In this patient, who was infected with SARS-CoV-2 and treated
with ICIs for metastatic RCC, an adequate cellular and humoral
immune response was measured, despite the presence of risk
factors for an impaired immune response and a severe course of
SARS-CoV-2. For instance, an increased risk for a severe course of
COVID-19 has been reported in patients who were treated with
high-dose steroids prior to hospital admission (7). In addition,
patients with cancer have an increased risk for a severe outcome of
COVID-19, and this further increases in patients with progressive
disease (6). Furthermore, this patient presented with lymphopenia,
which is considered a predictive marker for severe COVID-19 (14,
15). In particular, the patient had an increased neutrophil-to-
lymphocyte ratio (NLR)(6.5) and an increased lymphocyte-to-
monocyte ratio (LMR) (5.3) which are also considered markers of
poor survival in patients with COVID-19 (15). Finally, oncological
guidelines stress the enhanced risk of treatment with ICIs during
this pandemic (9, 17).
Besides the fact that this patient had several risk factors for an
impaired immune response and severe course of COVID-19,
adequate responses for both T and B cells were observed. T cell
activation and consequently differentiation (Figure 1) may have
led to loss of T cells, and an indirect increase in the fraction of
naïve CD4+ and CD8+ T cells. The increased frequencies of T cells
expressing immune receptors is another sign of T cell activation
and differentiation (Figure 2). In particular, the enhanced
frequency of CD4+ T cells expressing the co-inhibitory receptors
BTLA and PD-1 (Figure 2D), is considered the result of an
adaptive feedback loop to counter regulate the initial activation
of T cells (18, 19). In addition to T cells, also B cell activation was
observed by the production of neutralizing antibodies. As the viral
culture was already negative despite low titers of antibodies
measured with ELISA and PRNT50, the T cell response has
most likely contributed to the clearance of the virus. Overall,
both the presence of cellular as well as humoral immune
parameters was comparable to those observed in SARS-CoV-2
infected patients without cancer (18–20).
As shown, the patients’ immune system was sufficiently active
against SARS-CoV-2, but failed to act upon the renal cell cancer
effectively. The latter deficit may be due to the existence of immune
suppressive actions in the renal cell cancer micro-environment,
preventing effective infiltration and/or activation of anti-tumor T
cells (21). Already before COVID-19, the patient had progressive
disease according to RECIST v.1.1, indicating that the renal cell
cancer did not respond to immunotherapy. These results
underscore different obstacles to achieve anti-tumor versus anti-
virus immunity, and importantly demonstrate that, at least in this
case, treatment with ICI does not alter the anti-virus T and B
cell immunity.
Several studies have investigated the immune response to
SARS-CoV-2 (18–20), and have yielded limited and conflictingA
B
FIGURE 1 | Percentages of different maturation stages of CD4+ and CD8+
T cells. Fractions of CD4+ T cells (A) and CD8+ T cells (B) in four
differentiation stages at 3 time points: prior to ICIs (baseline), at 3 weeks
after first administration of ipilimumab plus nivolumab (T1), and during
SARS-CoV-2 infection (23 weeks after first administration of ipilimumab
plus nivolumab; T2). The figure shows percentages of the following stages
either within CD4+ and CD8+ T cells: naïve T cells (Tnaïve: CD45RA+,
CCR7+), central memory T cells (Tcm: CD45RA-, CCR7+), effector memory
T cells (Tem: CD45RA-, CCR7-), and effector memory T cells expressing
CD45RA (Temra: CD45A+, CCR7-).February 2021 | Volume 12 | Article 627186




FIGURE 2 | Percentages of CD4+ and CD8+ T cells expressing various classes of immune receptors. Fractions of CD4+ (left panels) and CD8+ (right panels) T cells
expressing <2 versus ≥ 2 different co-inhibitory receptors. (A), co-stimulatory receptors (B), and chemoattractant receptors (C) at 3 different time points: prior to ICIs
(baseline), at 3 weeks after first administration of ipilimumab plus nivolumab (T1), and during SARS-CoV-2 infection (23 weeks after first administration of ipilimumab
plus nivolumab; T2). An example of the expression of co-inhibitory receptors is shown in (D), where the fraction of CD4+ T cells co-expressing BTLA (CD272) and
PD-1 (CD279) at baseline, T1, and T2 is shown.Frontiers in Immunology | www.frontiersin.org February 2021 | Volume 12 | Article 6271864
de Joode et al. Case Report: SARS-CoV-2 After Immune Checkpoint Inhibitorsdata regarding COVID-19 in patients treated with ICIs (4, 9, 22).
To the best of our knowledge, this is the first report on adaptive
immunity in a SARS-CoV-2 infected patient treated with ICIs.
Limitations of this report include the description of only one
patient who had already discontinued treatment with ICIs.
Although the patient discontinued treatment with ICIs at 6
weeks prior to the onset of COVID-19, it is conceivable that
this treatment still affected the immune response. The ongoing
effects of ICIs are well-known and are usually illustrated by their
durable tumor response and late onset of adverse events, even
months to years after discontinuation of treatment. In addition,
specific measurements, such as NLR and LMR, were only
performed during COVID-19 and could not be compared to
previous values at baseline and during treatment with ICIs. The
role of innate immune cells in this patient could not be elucidated
in this particular case, and deserves further attention.
In conclusion, the adequate B and T cell responses in this
SARS-CoV-2 infected patient who was treated with ICIs, justify
renewed discussion on withholding of ICIs during the ongoing
COVID-19 pandemic and may guide inclusion of patients
treated with ICIs for COVID-19 vaccination (23).
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